Last Updated : June 26, 2024
Details
Generic Name:
remdesivir
Project Status:
Active
Therapeutic Area:
COVID-19 in hospitalized patients
Manufacturer:
Gilead Sciences Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Veklury
Project Line:
Reimbursement Review
Project Number:
SR0833-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Hospitalized patients 12 years of age (weighing at least 40 kg) with pneumonia requiring supplemental oxygen.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Hospitalized patients ≥12 years of age (weighing at least 40 kg) with pneumonia requiring supplemental oxygen.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 08-Jan-24 |
|---|---|
| Call for patient/clinician input closed | 04-Mar-24 |
| Clarification: - No patient input submission received | |
| Submission received | 01-Mar-24 |
| Submission accepted | 18-Mar-24 |
| Review initiated | 19-Mar-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 13-May-24 |
| Deadline for sponsors comments | 23-May-24 |
| CADTH review report(s) and responses to comments provided to sponsor | 14-Jun-24 |
| Expert committee meeting (initial) | 26-Jun-24 |
| Draft recommendation issued to sponsor | July 09, 2024 To July 11, 2024 |
| Draft recommendation posted for stakeholder feedback | 18-Jul-24 |
| End of feedback period | 01-Aug-24 |
Last Updated : June 26, 2024